JP2002541255A - Her族チロシンキナーゼの分解および/または阻害方法および組成物 - Google Patents
Her族チロシンキナーゼの分解および/または阻害方法および組成物Info
- Publication number
- JP2002541255A JP2002541255A JP2000610851A JP2000610851A JP2002541255A JP 2002541255 A JP2002541255 A JP 2002541255A JP 2000610851 A JP2000610851 A JP 2000610851A JP 2000610851 A JP2000610851 A JP 2000610851A JP 2002541255 A JP2002541255 A JP 2002541255A
- Authority
- JP
- Japan
- Prior art keywords
- geldanamycin
- chemical compound
- hsp
- compound according
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12859399P | 1999-04-09 | 1999-04-09 | |
| US60/128,593 | 1999-04-09 | ||
| PCT/US2000/009512 WO2000061578A1 (en) | 1999-04-09 | 2000-04-07 | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541255A true JP2002541255A (ja) | 2002-12-03 |
| JP2002541255A5 JP2002541255A5 (cg-RX-API-DMAC7.html) | 2007-07-05 |
Family
ID=22436066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000610851A Pending JP2002541255A (ja) | 1999-04-09 | 2000-04-07 | Her族チロシンキナーゼの分解および/または阻害方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7271160B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1169319A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002541255A (cg-RX-API-DMAC7.html) |
| AU (1) | AU769235B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2370007A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000061578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372712B1 (en) | 1998-05-22 | 2002-04-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand |
| US6887842B1 (en) * | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| AU2044001A (en) | 1999-11-19 | 2001-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Targeted bifunctional molecules and therapies based thereon |
| US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
| US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| ATE328888T1 (de) | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | Radicicol und monocillin und ihre analogen und ihre anwendungen |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| US7825094B2 (en) | 2001-05-23 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Method of treatment for cancers associated with elevated HER 2 levels |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| EP1923061A1 (en) | 2001-09-24 | 2008-05-21 | Conforma Therapeutic Corporation | Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins |
| JP2005504086A (ja) | 2001-09-24 | 2005-02-10 | コンフォーマ セラピューティクス コーポレーション | 17−アリルアミノゲルダナマイシン(17−aag)および他のアンサマイシン類を製造する方法 |
| GB0202871D0 (en) * | 2002-02-07 | 2002-03-27 | Cancer Res Ventures Ltd | Assays,methods and means |
| US7259156B2 (en) | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
| KR20070050918A (ko) * | 2004-07-02 | 2007-05-16 | 뉴텍 파마 피엘씨 | 암의 치료 |
| US20060105941A1 (en) * | 2004-11-12 | 2006-05-18 | Allergan, Inc. | Mixed antibiotic codrugs |
| BRPI0609509A2 (pt) | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2010028389A1 (en) * | 2008-09-08 | 2010-03-11 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP3738594A1 (en) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3099332A4 (en) | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| JP6576942B6 (ja) | 2014-03-03 | 2019-11-27 | マドリガル ファーマシューティカルズ インコーポレイテッド | 標的治療薬 |
| MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| US11377447B2 (en) | 2017-06-20 | 2022-07-05 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US11491145B2 (en) | 2017-06-20 | 2022-11-08 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| CN117700313B (zh) * | 2023-12-14 | 2025-02-14 | 怒江绿色香料产业研究院 | 一种羟基十四烯醛及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55111469A (en) * | 1979-02-19 | 1980-08-28 | Kaken Pharmaceut Co Ltd | Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient |
| JPH05148205A (ja) * | 1990-10-11 | 1993-06-15 | Merck & Co Inc | 対称構造を有するhivプロテアーゼ阻害剤 |
| JPH08506356A (ja) * | 1993-06-29 | 1996-07-09 | ファイザー・インク. | 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体 |
| WO1998051702A1 (en) * | 1997-05-14 | 1998-11-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5650430A (en) | 1990-06-06 | 1997-07-22 | Sankyo Company, Limited | Radicicol derivatives, their preparation and their anti-tumor activity |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| NZ331062A (en) | 1996-10-25 | 2000-05-26 | Kyowa Hakko Kogyo Company Ltd | Radicicol derivatives or pharmacologically acceptable salts which show tyrosine kinase inhibition activity and have antitumor effects |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
-
2000
- 2000-04-07 AU AU42235/00A patent/AU769235B2/en not_active Ceased
- 2000-04-07 WO PCT/US2000/009512 patent/WO2000061578A1/en not_active Ceased
- 2000-04-07 CA CA002370007A patent/CA2370007A1/en not_active Abandoned
- 2000-04-07 JP JP2000610851A patent/JP2002541255A/ja active Pending
- 2000-04-07 EP EP00921985A patent/EP1169319A4/en not_active Withdrawn
-
2001
- 2001-09-21 US US09/960,665 patent/US7271160B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55111469A (en) * | 1979-02-19 | 1980-08-28 | Kaken Pharmaceut Co Ltd | Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient |
| JPH05148205A (ja) * | 1990-10-11 | 1993-06-15 | Merck & Co Inc | 対称構造を有するhivプロテアーゼ阻害剤 |
| JPH08506356A (ja) * | 1993-06-29 | 1996-07-09 | ファイザー・インク. | 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体 |
| WO1998051702A1 (en) * | 1997-05-14 | 1998-11-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
Non-Patent Citations (4)
| Title |
|---|
| JPN6010057431, Cancer Chemother. Pharmacol., 1998, 42, 273−279 * |
| JPN6010057433, J.Med.Chem., 1995, 38, 3813−3820 * |
| JPN6010057435, Cell, 1997, 90, 65−75 * |
| JPN6010057437, Cell, 1997, 89, 239−250 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020045570A1 (en) | 2002-04-18 |
| WO2000061578A1 (en) | 2000-10-19 |
| AU769235B2 (en) | 2004-01-22 |
| EP1169319A4 (en) | 2005-02-09 |
| AU4223500A (en) | 2000-11-14 |
| US7271160B2 (en) | 2007-09-18 |
| EP1169319A1 (en) | 2002-01-09 |
| CA2370007A1 (en) | 2000-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7271160B2 (en) | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases | |
| CN109843335B (zh) | 吡咯并苯并二氮杂卓缀合物 | |
| US6391913B1 (en) | Derivatives of paclitaxel, method for producing same and uses thereof | |
| Zheng et al. | Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases | |
| TWI662968B (zh) | 配體-細胞毒性藥物偶聯物、其製備方法及其應用 | |
| Tang et al. | Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells | |
| EP3381474A1 (en) | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
| JP2022515250A (ja) | 改善された細胞標的化結合分子 | |
| JP2016505586A (ja) | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 | |
| TW202327661A (zh) | 抗her3抗體藥物偶聯物及其組合物和用途 | |
| JP2018507844A (ja) | 抗体薬物コンジュゲート | |
| JPH03161490A (ja) | メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬 | |
| HU208161B (en) | Process for producing cytotoxic active ingredient - antibody conjugates and pharmaceutical compositions | |
| US20100029758A1 (en) | Derivatives of isoflavones | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| Milazzo et al. | ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1 | |
| CN116036303B (zh) | 一种抗体-药物偶联物及其制备方法和应用 | |
| US20240398823A1 (en) | Dual inhibitor of histone deacetylase 6 and heat shock protein 90 | |
| WO2024073610A2 (en) | Compositions and uses thereof | |
| US20060052312A1 (en) | Paclitaxel hybrid derivatives | |
| EP3845231B1 (en) | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | |
| US7238682B1 (en) | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases | |
| US20040115209A1 (en) | Compound targeted for specific cells with reduced systemic toxicity | |
| TW202502388A (zh) | 包含抗cd138抗體之抗體藥物複合體 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070403 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110304 |